Connect Biopharma Holdings Limited (CNTB) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $9.00, representing an upside of 195.1% from the current price $3.05.
Analysts estimate Earnings Per Share (EPS) of $-0.03 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.28 vs est $-0.03 (missed -736.3%). 2025: actual $-1.00 vs est $-0.15 (missed -570.8%). Analyst accuracy: 13%.
CNTB Stock — 12-Month Price Forecast
$9.00
▲ +195.08% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Connect Biopharma Holdings Limited, the price target is $9.00.
The average price target represents a +195.08% change from the last price of $3.05.
CNTB Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Connect Biopharma Holdings Limited in the past 3 months
EPS Estimates — CNTB
13%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.28
vs Est –$0.03
▼ 88.0% off
2025
Actual –$1.00
vs Est –$0.15
▼ 85.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CNTB
13%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024
Actual $0.026B
vs Est $0.004B
▲ 86.5% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
